Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

@article{Hartman1991PharmacokineticsO2,
  title={Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.},
  author={Neil R. Hartman and Robert Yarchoan and James M. Pluda and Reuben. Thomas and Kathleen M. Wyvill and Karl P. Flora and Samuel E Broder and David G. Johns},
  journal={Clinical pharmacology and therapeutics},
  year={1991},
  volume={50 3},
  pages={278-85}
}
2',3'-Dideoxyinosine (ddI) has shown activity against human immunodeficiency virus in phase I clinical trials. The drug is rapidly degraded by acid, however, thus raising questions as to the efficiency and reproducibility of its absorption after oral administration. This investigation studies the bioavailability of several oral dosage forms of ddI. When ddI was given to fasting patients as an oral solution with antacid, the bioavailability was 41% +/- 7% (mean +/- SEM). However, when given as… CONTINUE READING